# Olive Leaf Sleep Meta-analysis: What the Evidence Says
Canonical: https://www.migaku.app/guides/olive-leaf-sleep-meta-analysis-evidence-review
Category: evidence-review
Summary: Olive Leaf Sleep Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed bi
Last reviewed: 2026-07-26
Reviewed by: Migaku Evidence Review
# Olive Leaf Sleep Meta-analysis: What the Evidence Says

## Quick Answer

Olive Leaf Sleep Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 2 narrative review.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Natural Molecules for Brain Health and Resilience | narrative review | 3 | 2026-05-13 | 10.3390/ijms27104343 |
| Summary of the best evidence for non-pharmacological interventions for dyslipidemia in patients with coronary heart disease | narrative review | 3 | 2026-03-11 | 10.3389/fcvm.2026.1753853 |

## What The Sources Report

- Figure 1 Thus, in the present review we aimed to summarize the preclinical and clinical evidence of selected nutraceuticals, focusing on biotin, flavonoids especially luteolin, folic acid, Huperzine A, Lion's mane, olive oil polyphenols (oleuropein and hydroxytyrosol [HT]), and palmitoylethanolamide (PEA). [Venetsanaki Vasiliki (2026); evidence level 3]
- The present narrative review highlights current mechanistic insights, as well as evidence from experimental and clinical studies regarding their potential roles in supporting cognitive function, modulating neuroinflammation, and mitigating neurodegenerative processes. [Venetsanaki Vasiliki (2026); evidence level 3]
- Research indicates that in developed countries, effective control of risk factors and rational allocation of medical resources have led to a declining trend in CHD prevalence. [Zeng Zhi (2026); evidence level 3]
- Dyslipidemia is a major risk factor for CHD recurrence and mortality and is primarily manifested as elevated serum levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglycerides, coupled with reduced levels of high-density lipoprotein cholesterol (HDL-C). [Zeng Zhi (2026); evidence level 3]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

For olive leaf sleep meta-analysis, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Venetsanaki Vasiliki (2026). Natural Molecules for Brain Health and Resilience. DOI: 10.3390/ijms27104343. PMCID: PMC13207114. PMID: 42196321. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13207114/
- Zeng Zhi (2026). Summary of the best evidence for non-pharmacological interventions for dyslipidemia in patients with coronary heart disease. DOI: 10.3389/fcvm.2026.1753853. PMCID: PMC13013076. PMID: 41890873. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13013076/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.